PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

Phase 2 clinical trial finds 177Lu-Dotatate may extend progression-free survival for patients with no other options to manage recurrent disease

2024-09-29
(Press-News.org) WASHINGTON, September 29, 2024 — A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. 

“We’ve found a therapy with a meaningful signal for effectiveness and safety for people with refractory meningioma, a condition with no standard treatment options,” said Kenneth W. Merrell, MD, principal investigator (PI) of the trial and a radiation oncologist at the Mayo Clinic Alix School of Medicine in Rochester, Minn.

“Nearly 80% of patients in our study were progression-free after six months. This rate greatly surpassed the benchmark from prior research, suggesting that radiopharmaceuticals are a promising therapeutic agent for these patients.”

Meningiomas are tumors that grow in the connective tissue surrounding the brain and spinal cord. They are the most common type of primary brain tumor, and while they typically do not spread to other parts of the body, they can grow uncontrollably and lead to disabling and deadly compression of the nerves and brain.

Standard treatment for patients with meningiomas is either surgical removal or external beam radiation therapy when tumors grow in areas where surgery is too dangerous, such as close to the brain stem or spinal cord. But for the portion of patients where the tumor grows despite these treatments, known as refractory meningioma, the tumors tend to behave more aggressively, and retreatment is difficult because radiation and surgery cannot be repeated frequently without greater risks.

“There is no standard of care or proven option for managing refractory meningioma. Many of these patients continue to experience aggressive tumor growth and significant related complications, and ultimately the illness may prove fatal. It is a very challenging prognosis to manage, and in many cases, we are left with only supportive measures,” Dr. Merrell said.

Dr. Merrell and his colleagues investigated whether patients with refractory meningioma would benefit from theranostics, an approach that combines therapy with diagnostics for personalized internal delivery of radiation treatment. Theranostics leverages radiopharmaceuticals — specialized medicine containing radioactive material — to find cancer cells in the body and attack them with precise doses of radiation, without harming the surrounding healthy tissue. This dual-pronged approach offers patients a more tailored, and potentially more effective, treatment option.

While still an emerging treatment modality, radiopharmaceuticals are commonly used to treat thyroid cancer, metastatic cancer such as bone metastases from prostate cancer, and other types of tumors. For this trial, researchers looked specifically at 177Lu-Dotatate, an FDA-approved radiopharmaceutical for neuroendocrine tumors, which share biological similarities with meningiomas.

“There have been many attempts at testing a variety of chemotherapies and other systemic agents for these patients. And others have looked at this option for therapy, but no one had completed a prospective trial for this patient population before ours,” said Geoffrey B. Johnson, MD, PhD, the co-PI of the trial and a nuclear medicine physician at the Mayo Clinic.

“With advanced PET imaging, the theranostic approach to treatment helps us to select those patients most likely to benefit from molecularly targeted radiation directly to their tumor cells.”

The researchers conducted a single-arm, phase II clinical trial at a large academic center, enrolling patients with refractory meningioma that had grown at a rate of 15% or more over a six-month period. During a three-year period beginning in April 2020, patients including 20 people with WHO grade 2 or 3 disease were enrolled into the study. The median patient age was 67, and nearly all (95%) had grade 2 meningiomas. Trial participants received four infusions of 177Lu-Dotatate spaced eight weeks apart.

Six months after treatment, 78% of patients had not experienced further tumor progression, far exceeding the benchmark progression-free survival rate of 26% established by prior research. The median time before patients’ cancer progressed was 11.5 months.

After one year, overall survival was 88.9%. No patients experienced life-threatening side effects, while 10 had severely low blood counts, one had grade 3 hepatitis and one had a grade 3 seizure possibly related to treatment. Five patients did not complete treatment due to tumor progression (n=2), adverse events possibly related to treatment (n=2) or other comorbidities (n-1).

“Most patients tolerated the treatment well,” Dr. Merrell said. “It appears that 177Lu-Dotatate is a safe and rational therapeutic choice with broad eligibility for patients with aggressively growing meningiomas, particularly as alternative therapy options are limited.”

“As there is no current standard of care for these patients, our findings establish a new benchmark and may influence the treatment options available.”

###

This press release contains updated findings/data from the study authors.

Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested in all coverage.

Study/Presentation Details

Abstract 2: A prospective, phase II study of 177Lu-Dotatate in patients with surgery- and radiation- refractory meningioma: Results of the WHO grade II/III cohort News Briefing: Tuesday, October 1, 9:00 a.m. Eastern time. Details here. Register here. Scientific Presentation: Sunday, September 29, 1:00 p.m. Eastern time, Walter E. Washington Convention Center. Email press@astro.org to access the livestream or recording. This was an investigator initiated clinical trial, with funding to support from Novartis. ABOUT ASTRO

The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. Radiation therapy contributes to 40% of global cancer cures, and more than a million Americans receive radiation treatments for cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and follow us on social media.

WASHINGTON, September 29, 2024 — A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. 

“We’ve found a therapy with a meaningful signal for effectiveness and safety for people with refractory meningioma, a condition with no standard treatment options,” said Kenneth W. Merrell, MD, principal investigator (PI) of the trial and a radiation oncologist at the Mayo Clinic Alix School of Medicine in Rochester, Minn.

“Nearly 80% of patients in our study were progression-free after six months. This rate greatly surpassed the benchmark from prior research, suggesting that radiopharmaceuticals are a promising therapeutic agent for these patients.”

Meningiomas are tumors that grow in the connective tissue surrounding the brain and spinal cord. They are the most common type of primary brain tumor, and while they typically do not spread to other parts of the body, they can grow uncontrollably and lead to disabling and deadly compression of the nerves and brain.

Standard treatment for patients with meningiomas is either surgical removal or external beam radiation therapy when tumors grow in areas where surgery is too dangerous, such as close to the brain stem or spinal cord. But for the portion of patients where the tumor grows despite these treatments, known as refractory meningioma, the tumors tend to behave more aggressively, and retreatment is difficult because radiation and surgery cannot be repeated frequently without greater risks.

“There is no standard of care or proven option for managing refractory meningioma. Many of these patients continue to experience aggressive tumor growth and significant related complications, and ultimately the illness may prove fatal. It is a very challenging prognosis to manage, and in many cases, we are left with only supportive measures,” Dr. Merrell said.

Dr. Merrell and his colleagues investigated whether patients with refractory meningioma would benefit from theranostics, an approach that combines therapy with diagnostics for personalized internal delivery of radiation treatment. Theranostics leverages radiopharmaceuticals — specialized medicine containing radioactive material — to find cancer cells in the body and attack them with precise doses of radiation, without harming the surrounding healthy tissue. This dual-pronged approach offers patients a more tailored, and potentially more effective, treatment option.

While still an emerging treatment modality, radiopharmaceuticals are commonly used to treat thyroid cancer, metastatic cancer such as bone metastases from prostate cancer, and other types of tumors. For this trial, researchers looked specifically at 177Lu-Dotatate, an FDA-approved radiopharmaceutical for neuroendocrine tumors, which share biological similarities with meningiomas.

“There have been many attempts at testing a variety of chemotherapies and other systemic agents for these patients. And others have looked at this option for therapy, but no one had completed a prospective trial for this patient population before ours,” said Geoffrey B. Johnson, MD, PhD, the co-PI of the trial and a nuclear medicine physician at the Mayo Clinic.

“With advanced PET imaging, the theranostic approach to treatment helps us to select those patients most likely to benefit from molecularly targeted radiation directly to their tumor cells.”

The researchers conducted a single-arm, phase II clinical trial at a large academic center, enrolling patients with refractory meningioma that had grown at a rate of 15% or more over a six-month period. During a three-year period beginning in April 2020, patients including 20 people with WHO grade 2 or 3 disease were enrolled into the study. The median patient age was 67, and nearly all (95%) had grade 2 meningiomas. Trial participants received four infusions of 177Lu-Dotatate spaced eight weeks apart.

Six months after treatment, 78% of patients had not experienced further tumor progression, far exceeding the benchmark progression-free survival rate of 26% established by prior research. The median time before patients’ cancer progressed was 11.5 months.

After one year, overall survival was 88.9%. No patients experienced life-threatening side effects, while 10 had severely low blood counts, one had grade 3 hepatitis and one had a grade 3 seizure possibly related to treatment. Five patients did not complete treatment due to tumor progression (n=2), adverse events possibly related to treatment (n=2) or other comorbidities (n-1).

“Most patients tolerated the treatment well,” Dr. Merrell said. “It appears that 177Lu-Dotatate is a safe and rational therapeutic choice with broad eligibility for patients with aggressively growing meningiomas, particularly as alternative therapy options are limited.”

“As there is no current standard of care for these patients, our findings establish a new benchmark and may influence the treatment options available.”

###

This press release contains updated findings/data from the study authors.

Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested in all coverage.

Study/Presentation Details

Abstract 2: A prospective, phase II study of 177Lu-Dotatate in patients with surgery- and radiation- refractory meningioma: Results of the WHO grade II/III cohort News Briefing: Tuesday, October 1, 9:00 a.m. Eastern time. Details here. Register here. Scientific Presentation: Sunday, September 29, 1:00 p.m. Eastern time, Walter E. Washington Convention Center. Email press@astro.org to access the livestream or recording. This was an investigator initiated clinical trial, with funding to support from Novartis. ABOUT ASTRO

The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. Radiation therapy contributes to 40% of global cancer cures, and more than a million Americans receive radiation treatments for cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and follow us on social media.

END


ELSE PRESS RELEASES FROM THIS DATE:

American Academy of Pediatrics promotes shared reading starting in infancy as a positive parenting practice with lifelong benefits

2024-09-29
ORLANDO, Fla.--The American Academy of Pediatrics encourages parents and caregivers to read aloud with their newborns and young children as an opportunity to foster loving, nurturing relationships during a critical time of brain development, and recommends that pediatricians support families with guidance and books at well-child visits, according to an updated policy statement. The policy statement, “Literacy Promotion: An Essential Component of Primary Care Pediatric Practice,” marks the first update in AAP recommendations since 2014. Given the extraordinary amount of research in this area, an accompanying ...

Unexpected human behaviour revealed in prisoner's dilemma study: Choosing cooperation even after defection

2024-09-28
The study also examined the impact of different game structures, such as simultaneous versus alternating decision-making, and the option of voluntary participation. The results showed that these variations significantly influence participants' cooperation rate.   The research reveals that people tend to cooperate even after being defected, which contradicts many traditional game theory models. "This finding is particularly fascinating because it suggests that humans are more forgiving and cooperative than previously thought," said Dr. Hitoshi Yamamoto, the study's lead researcher.   The ...

Distant relatedness in biobanks harnessed to identify undiagnosed genetic disease

Distant relatedness in biobanks harnessed to identify undiagnosed genetic disease
2024-09-27
An innovative analysis of shared segments within the genome — an indication of distant “relatedness” — has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal heart rhythms, fainting and sudden cardiac death.   The findings, reported in the journal Nature Communications, illustrate the feasibility of the new approach developed by researchers at Vanderbilt University Medical Center to detect undiagnosed carriers of rare ...

UCLA at ASTRO: Predicting response to chemoradiotherapy in rectal cancer, 2-year outcomes of MRI-guided radiotherapy for prostate cancer, impact of symptom self-reporting during chemoradiation and mor

2024-09-27
UCLA Health Jonsson Comprehensive Cancer Center researchers and physicians who specialize in treating patients with radiation therapies will present data on the latest radiation oncology research and clinical trial results at the 66th annual American Society for Radiation Oncology (ASTRO) meeting in Washington D.C., Sept. 29 to Oct. 2. The annual meeting, which is the leading meeting in radiation oncology, will feature 23 abstracts from UCLA investigators that highlight key areas of radiation oncology, including new research in subspecialties ranging from survivorship, lung cancer/thoracic malignancies, physics, sarcoma, gastrointestinal cancer, genitourinary cancer, gynecological ...

Estimated long-term benefits of finerenone in heart failure

2024-09-27
About The Study: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone was estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction.  Corresponding Author: To contact the corresponding author, Scott D. Solomon, M.D., email ssolomon@rics.bwh.harvard.edu. To access the embargoed study: Visit our For The Media website at ...

MD Anderson launches first-ever academic journal: Advances in Cancer Education & Quality Improvement

MD Anderson launches first-ever academic journal: Advances in Cancer Education & Quality Improvement
2024-09-27
The University of Texas MD Anderson Cancer Center today announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement (ACE-QI). The journal will publish research, training program summaries and quality improvement interventions for the oncology provider community. The open-access, peer-reviewed journal will feature research and professional perspectives focused on training health care providers to meet myriad challenges around prevention, diagnosis, treatment and survivorship in cancer care. “We envision this journal as a catalyst for critical conversations across the cancer care continuum," said Joshua Kuban, M.D., associate ...

Penn Medicine at the 2024 ASTRO Annual Meeting

2024-09-27
PHILADELPHIA – Leading experts in radiation therapy from Penn Medicine’s Abramson Cancer Center and the Perelman School of Medicine will present new results from clinical trials and research studies at the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting, which will be held at the Walter E. Washington Convention Center in Washington, D.C., Sept. 29 through Oct. 2, 2024. At the meeting, Neha Vapiwala, MD, FACR, FASTRO, FASCO, the Eli Glatstein Professor in Radiation Oncology, will take office as president-elect of ASTRO as the first Penn faculty member to lead the premier society ...

Head and neck, meningioma research highlights of University of Cincinnati ASTRO abstracts

2024-09-27
University of Cincinnati Cancer Center experts will present research at the American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 29 through Oct. 2.  Osteoradionecrosis more common in patients with head and neck cancer that requires partial jaw removal  Following radiation treatment for head and neck cancer, some patients can experience osteoradionecrosis (ORN) when an area of exposed bone fails to heal after a three-month period.  “ORN of the mandible and maxilla (jaw bones) can be very debilitating, as it often causes severe pain, fistula formation, infection and susceptibility to fractures,” ...

Center for BrainHealth receives $2 million match gift from Adm. William McRaven (ret.), recipient of Courage & Civility Award

Center for BrainHealth receives $2 million match gift from Adm. William McRaven (ret.), recipient of Courage & Civility Award
2024-09-27
Center for BrainHealth® at The University of Texas at Dallas has received a major match gift commitment from retired U.S. Navy four-star admiral and former University of Texas System chancellor William McRaven and his wife Georgeann. Adm. McRaven recently received the 2024 Bezos Courage & Civility Award presented by Amazon founder Jeff Bezos and Lauren Sánchez.   The $2 million challenge grant will support Optimal BrainHealth for Warfighters – including active-duty military, spouses and veterans. This program will help those with traumatic brain injury (TBI), post-traumatic stress (PTS) and similar issues, as well ...

Circadian disruption, gut microbiome changes linked to colorectal cancer progression

2024-09-27
Irvine, Calif., Sept. 27, 2024 — Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body’s internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function. This discovery offers new avenues for prevention and treatment strategies.   The study, published online today in the journal Science Advances, offers a more comprehensive understanding of how important changes occur in the function and composition of the gut microbiome when the circadian clock is disturbed in the presence ...

LAST 30 PRESS RELEASES:

Scientists discover a secret to regulating our body clock, offering new approach to end jet lag

Impact of pollutants on pollinators, and how neural circuits adapt to temperature changes

Researchers seek to improve advanced pain management using AI for drug discovery

‘Neutron Nexus’ brings universities, ORNL together to advance science

Early release from NEJM Evidence

UMass Amherst astronomer leads science team helping to develop billion-dollar NASA satellite mission concept

Cultivating global engagement in bioengineering education to train students skills in biomedical device design and innovation

Life on Earth was more diverse than classical theory suggests 800 million years ago, a Brazilian study shows

International clean energy initiative launches global biomass resource assessment

How much do avoidable deaths impact the economy?

Federal government may be paying twice for care of veterans enrolled in Medicare Advantage plans

New therapeutic target for cardiac arrhythmias emerges

UC Irvine researchers are first to reveal role of ophthalmic acid in motor function control

Moffitt study unveils the role of gamma-delta T cells in cancer immunology

Drier winter habitat impacts songbirds’ ability to survive migration

Donors enable 445 TPDA awards to Neuroscience 2024

Gut bacteria engineered to act as tumor GPS for immunotherapies

Are auditory magic tricks possible for a blind audience?

Research points to potential new treatment for aggressive prostate cancer subtype

Studies examine growing US mental health safety net

Social risk factor domains and preventive care services in US adults

Online medication abortion direct-to-patient fulfillment before and after the Dobbs v Jackson decision

Black, Hispanic, and American Indian adolescents likelier than white adolescents to be tested for drugs, alcohol at pediatric trauma centers

Pterosaurs needed feet on the ground to become giants

Scientists uncover auditory “sixth sense” in geckos

Almost half of persons who inject drugs (PWID) with endocarditis will die within five years; women are disproportionately affected

Experimental blood test improves early detection of pancreatic cancer

Groundbreaking wastewater treatment research led by Oxford Brookes targets global challenge of toxic ‘forever chemicals’

Jefferson Health awarded $2.4 million in PCORI funding

Cilta-cel found highly effective in first real-world study

[Press-News.org] Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors
Phase 2 clinical trial finds 177Lu-Dotatate may extend progression-free survival for patients with no other options to manage recurrent disease